Suzetrigine – complimentary MARA Rating report: pricing & reimbursement risk assessment for neuropathic pain. This complimentary MARA Rating® report reviews Suzetrigine’s access profile in the treatment of neuropathic pain. The
Tolebrutinib – complimentary MARA Rating report: pricing & reimbursement risk assessment for secondary progressive multiple sclerosis. This complimentary MARA Rating® report examines Tolebrutinib’s market-access risk profile for treating non-relapsing secondary
Survodutide – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity treatment. This complimentary MARA Rating® report assesses Survodutide’s market-access risk profile for the treatment of obesity. The
Retatrutide – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity and metabolic disorders. This complimentary MARA Rating® report assesses Retatrutide for obesity with or without metabolic disorders.
Orforglipron – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity and type 2 diabetes. This complimentary MARA Rating® report reviews Orforglipron’s market-access profile for the treatment of
Brensocatib – complimentary MARA Rating report: pricing & reimbursement risk assessment for non-cystic fibrosis bronchiectasis. Brensocatib has undergone evaluation through the MARA Rating framework to assess its market-access prospects for